Fuente: ABBVIE SPAIN, S.L.U.

J Am Acad Dermatol. 2018 Jun 1. pii: S0190-9622(18)30836-3. doi: 10.1016/j.jaad.2018.05.040. [Epub ahead of print]
Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa: 3-year results of a phase 3 open-label extension study.
Zouboulis CC1, Okun MM2, Prens EP3, Gniadecki R4, Foley PA5, Lynde C6, Weisman J7, Gu Y8, Williams DA8, Jemec GBE9.

Br J Dermatol. 2018 Feb;178(2):509-519. doi: 10.1111/bjd.16102. Epub 2018 Jan 9.
Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis.
Egeberg A1, Ottosen MB1, Gniadecki R2, Broesby-Olsen S3, Dam TN4, Bryld LE5, Rasmussen MK6, Skov L1

J Eur Acad Dermatol Venereol. 2018 Oct;32(10):1737-1744. doi: 10.1111/jdv.15077. Epub 2018 Jun 1.
Psoriasis Area and Severity Index response in moderate-severe psoriatic patients switched to adalimumab: results from the OPPSA study.
Talamonti M1, Galluzzo M1, Bernardini N2, Caldarola G3, Persechino S4, Cantoresi F5, Egan CG6, Potenza C2, Peris K3, Bianchi L1

J Dermatolog Treat. 2015 Feb;26(1):49-53. doi: 10.3109/09546634.2014.880775. Epub 2014 Feb 20.
Efficacy of adalimumab in the treatment of moderate-to-severe psoriasis: A retrospective study of 100 patients in daily practice.
Armesto S1, Coto-Segura P, Mayorga J, Illaro A, Santos-Juanes J